27569032|t|A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy
27569032|a|Solid lipid-polymer hybrid nanocarrier (LPN) was previously reported to achieve high siRNA transfection efficiency and induce sustained RNAi -based chemosensitizing effect at cellular level. In this study, our objectives were to evaluate the in vivo biodistribution of LPNs in a prostate cancer model and determine the factors that potentially affect tumor penetration by LPNs. The LPN formulation with the highest transfection efficiency (64%) and stability was selected for the study. Mice bearing tumors of PC-3Mcells were treated with LPNs labeled with IR780 or AF647 - siRNA. Near infrared imaging showed that LPNs achieved favorable in vivo biodistribution with high tumor /low organ ratios. LPN accumulation was also observed in liver metastatic tissue. Result of extravasation study confirmed that encapsulated siRNA molecules were able to escape into the tumor tissue at the extravascular area. When LPN levels in large (volume >750mm(3)) and small (<500mm(3)) tumors were compared, no significant difference was observed. However, both docetaxel pretreatment (72hbefore LPN) and concurrent docetaxel treatment significantly enhanced the tumor LPN levels by 3.9- and 3.1-fold, respectively (both p<0.01). In conclusion, LPN is a promising carrier system to deliver RNAi therapy to solid malignancies that also receive chemotherapy.
27569032	18	23	study	T062	UMLS:C2603343
27569032	27	75	solid lipid-polyethyleneimine hybrid nanocarrier	T103	UMLS:C0013161
27569032	80	86	cancer	T038	UMLS:C0006826
27569032	87	99	RNAi therapy	T058	UMLS:C4042855
27569032	100	138	Solid lipid-polymer hybrid nanocarrier	T103	UMLS:C0013161
27569032	140	143	LPN	T103	UMLS:C0013161
27569032	185	190	siRNA	T103	UMLS:C1099354
27569032	191	203	transfection	T062	UMLS:C0040669
27569032	236	240	RNAi	T038	UMLS:C1136031
27569032	248	271	chemosensitizing effect	T201	UMLS:C1527144
27569032	299	304	study	T062	UMLS:C2603343
27569032	342	349	in vivo	T082	UMLS:C1515655
27569032	369	373	LPNs	T103	UMLS:C0013161
27569032	379	394	prostate cancer	T038	UMLS:C0600139
27569032	451	456	tumor	T038	UMLS:C0027651
27569032	472	476	LPNs	T103	UMLS:C0013161
27569032	482	485	LPN	T103	UMLS:C0013161
27569032	486	497	formulation	T103	UMLS:C0013058
27569032	515	527	transfection	T062	UMLS:C0040669
27569032	580	585	study	T062	UMLS:C2603343
27569032	587	591	Mice	T204	UMLS:C0025929
27569032	600	606	tumors	T038	UMLS:C0027651
27569032	610	620	PC-3Mcells	T017	UMLS:C1513528
27569032	639	643	LPNs	T103	UMLS:C0013161
27569032	657	662	IR780	T103	UMLS:C2933062
27569032	666	671	AF647	T103	UMLS:C3489916
27569032	674	679	siRNA	T103	UMLS:C1099354
27569032	681	702	Near infrared imaging	T058	UMLS:C4288612
27569032	715	719	LPNs	T103	UMLS:C0013161
27569032	739	746	in vivo	T082	UMLS:C1515655
27569032	773	778	tumor	T038	UMLS:C0027651
27569032	784	789	organ	T017	UMLS:C0178784
27569032	798	801	LPN	T103	UMLS:C0013161
27569032	802	814	accumulation	T033	UMLS:C4055506
27569032	836	841	liver	T017	UMLS:C0023884
27569032	842	859	metastatic tissue	T017	UMLS:C0475358
27569032	871	884	extravasation	T038	UMLS:C0015376
27569032	885	890	study	T062	UMLS:C2603343
27569032	919	924	siRNA	T103	UMLS:C1099354
27569032	964	976	tumor tissue	T017	UMLS:C0475358
27569032	984	1002	extravascular area	T082	UMLS:C0005898
27569032	1009	1012	LPN	T103	UMLS:C0013161
27569032	1070	1076	tumors	T038	UMLS:C0027651
27569032	1146	1155	docetaxel	T103	UMLS:C0246415
27569032	1180	1183	LPN	T103	UMLS:C0013161
27569032	1200	1209	docetaxel	T103	UMLS:C0246415
27569032	1210	1219	treatment	T058	UMLS:C0087111
27569032	1247	1252	tumor	T038	UMLS:C0027651
27569032	1253	1256	LPN	T103	UMLS:C0013161
27569032	1329	1332	LPN	T103	UMLS:C0013161
27569032	1348	1362	carrier system	T103	UMLS:C0013161
27569032	1374	1386	RNAi therapy	T058	UMLS:C4042855
27569032	1390	1408	solid malignancies	T038	UMLS:C4282132
27569032	1427	1439	chemotherapy	T058	UMLS:C3665472